Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine
Financing led by new investor TCGX, alongside Goldman Sachs Alternatives, Avoro Ventures and venBio Funding will support and accelerate development of next-generation multivalent respiratory virus vaccines using proprietary Molecular Clamp technology Commenced Phase I clinical study of bivalent vaccine targeting both Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) LONDON, Sept. 23, 2024 /PRNewswire/ — Vicebio Ltd (“Vicebio”), a biopharmaceutical […]
Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda as Chief Executive Officer and Member of the Board of Directors
Company actively advancing lead ophthalmology drug candidate to first Investigational New Drug (IND) filing
Candid Therapeutics Debuts with $370M Capital Raise
SAN DIEGO–(BUSINESS WIRE)–Candid Therapeutics, Inc. (“Candid”), a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases, announced its official launch today. “TCE antibodies have the most promise as scalable and patient friendly drugs to deplete B cells for treatment of a myriad of autoimmune conditions and represents a once in a generation […]
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the pricing of its upsized initial public offering of 13,920,000 shares of common stock at a price […]
Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors
FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) — Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades of industry leadership experience, including early- and late-stage therapeutic […]
Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives
— Proceeds support advancing Attovia’s lead programs through initial clinical readouts, expanding its pipeline, and ongoing development of the ATTOBODY™ platform — Financing led by Goldman Sachs Alternatives with participation by new and existing investors FREMONT, Calif., May 09, 2024 (GLOBE NEWSWIRE) — Attovia Therapeutics today announced the closing of a $105 million oversubscribed Series […]
AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING
First Cohort of Participants Dosed in Phase 1 Clinical Trial with Lead Development Candidate AV078 Intended for the Treatment of Seizures Associated with Tuberous Sclerosis Complex (TSC) Leadership Team Strengthened with the Appointment of William Greene, MD, CIO at Hevolution, and Justin Gover, Former CEO at GW Pharmaceuticals to the Board of Directors, and Micah Zajic Appointed as […]
Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction
– Financing led by Foresite Capital, Samsara BioCapital and venBio Partners with participation from additional new and existing investors –– Proceeds will support ongoing comprehensive mid to late-stage clinical development program for ESK-001 in plaque psoriasis, systemic lupus erythematosus (SLE) and uveitis –– Alumis will continue to explore ESK-001’s potential application in other immune-mediated diseases, […]
Q&A: Ken Song details RayzeBio’s path from Series A to IPO in 3 years
Ken Song almost never got into radiopharmaceuticals. But after back-to-back phone calls from venture capital leaders at Versant and venBio in March 2020, the repeat life sciences CEO took a deep dive into the field, which at that point was outside the radar of most people in drug development. Those calls worked, and Song would […]
Attralus Closes $56 Million Financing
SAN FRANCISCO – February 06, 2024 – Attralus, Inc., a clinical-stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that it has closed a $56 million financing. The financing round was led by new investor Alpha Wave Ventures and also included Bristol Myers Squibb (BMY). Existing investors also […]
